van den BergBWalgaardCDrenthenJFokkeCJacobsBCvan DoornPA.Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469-482. doi:10.1038/nrneurol.2014.121
2.
JonesHRJr.Guillain-Barré syndrome: perspectives with infants and children. Semin Pediatr Neurol. 2000;7:91-102. doi:10.1053/pb.2000.6690
RudantJDupontAMikaeloffYBolgertFCosteJWeillA.Surgery and risk of Guillain-Barré syndrome: a French nationwide epidemiologic study. Neurology. 2018;91:e1220-e1227. doi:10.1212/WNL.0000000000006246
5.
YukiNHartungHP.Guillain-Barré syndrome. N Engl J Med. 2012;366:2294-2304. doi:10.1056/NEJMra1114525
6.
SejvarJJBaughmanALWiseMMorganOW.Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123-133. doi:10.1159/000324710
7.
CavannaBJiangHAllariaSCarpoMScarlatoGNobile-OrazioE.Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies. J Neuroimmunol. 2001;114:226-231. doi:10.1016/s0165-5728(00)00461-6
8.
KimJKKimYHYoonBA, et al. Clinical heterogeneity of anti-GM2-ganglioside-antibody syndrome. J Clin Neurol. 2018;14:401-406. doi:10.3988/jcn.2018.14.3.401
9.
NaikGSMeenaAKReddyBAMridulaRKJabeenSABorgohainR.Anti-ganglioside antibodies profile in Guillain-Barré syndrome: correlation with clinical features, electrophysiological pattern, and outcome. Neurol India. 2017;65:1001-1005. doi:10.4103/neuroindia.NI_1226_15
10.
IrieSSaitoTNakamuraK, et al. Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol. 1996;68:19-26. doi:10.1016/0165-5728(96)00059-8
11.
LunnMHughesR.The relationship between cytomegalovirus infection and Guillain-Barré syndrome. Clin Infect Dis. 2011;52:845-847. doi:10.1093/cid/cir082
12.
VisserLHvan der MecheFGMeulsteeJ, et al. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology. 1996;47:668-673. doi:10.1212/wnl.47.3.668
13.
SpagnoliCIodiceASalernoGG, et al. CMV-associated axonal sensory-motor Guillain-Barré syndrome in a child: case report and review of the literature. Eur J Paediatr Neurol. 2016;20:168-175. doi:10.1016/j.ejpn.2015.11.004
Khalili-ShiraziAGregsonNGrayIReesJWinerJHughesR. Antiganglioside antibodies in GuillaineBarre syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry. 1999;66:376e9. doi:10.1136/jnnp.66.3.376
16.
MurakamiNTomitaYKogaM, et al. An adolescent with pharyngeal-cervical-brachial variant of GuillaineBarre syndrome after cytomegalovirus infection. Brain Dev. 2006;28:269e71. doi:10.1016/j.braindev.2005.08.004
17.
MendizabalJEBassamBA. GuillaineBarre syndrome and cytomegalovirus infection during pregnancy. South Med J. 1997;90:63e4. doi:10.1097/00007611-199701000-00014
18.
HughesRAWijdicksEFBensonE, et al; Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005;62:1194-1198. doi:10.1001/archneur.62.8.1194
19.
PatwaHSChaudhryVKatzbergHRae-GrantADSoYT.Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78:1009-1015. doi:10.1212/WNL.0b013e31824de293
20.
FarcasPAvnunLFrisherSHerishanuYOWirguinI.Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet. 1997;350:1747. doi:10.1016/s0140-6736(97)24050-x
21.
Oczko-WalkerMManousakisGWangSMalterJSWaclawikAJ.Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis. 2010;12:55-61. doi:10.1097/CND.0b013e3181f3dbbf
